Related Experiment Video

Updated: Jun 6, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

16.8K

Breathing down resistance: Tackling hypoxia to overcome immunotherapy barriers in lung cancer

Huanhuan Joyce Chen1,2

  • 1The Pritzker School of Molecular Engineering, Cummings Life Science Center, The University of Chicago , Chicago, IL, USA.

The Journal of Experimental Medicine
|November 25, 2024
PubMed

Insights

Tumor hypoxia drives resistance to immune checkpoint inhibitors in non-small cell lung cancer. Targeting hypoxic regions with hypoxia-activated pro-drugs may overcome this resistance, improving cancer therapy outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer (NSCLC) treatment.
  • Acquired resistance to ICIs remains a significant clinical challenge in NSCLC management.
  • Tumor hypoxia is increasingly recognized as a key factor contributing to therapeutic resistance.

Purpose of the Study:

  • To investigate the role of tumor hypoxia in acquired resistance to immune checkpoint inhibitors in non-small cell lung cancer.
  • To evaluate the potential of targeting hypoxic tumor regions to overcome ICI resistance.

Main Methods:

  • The study by Robles-Oteiza et al. links tumor hypoxia to acquired resistance mechanisms in NSCLC treated with ICIs.
  • The research advocates for the use of hypoxia-activated pro-drugs, exemplified by TH-302, to target these specific tumor microenvironments.

Main Results:

  • Compelling evidence demonstrates a direct link between tumor hypoxia and the development of resistance to ICI therapy in NSCLC.
  • Targeting hypoxic tumor regions with hypoxia-activated pro-drugs shows promise in delaying the onset of acquired resistance.

Conclusions:

  • Tumor hypoxia is a critical mediator of acquired resistance to immune checkpoint inhibitors in non-small cell lung cancer.
  • Hypoxia-activated pro-drugs represent a promising therapeutic strategy to overcome ICI resistance and improve treatment efficacy in NSCLC.

More Related Videos

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment09:02

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Published on: June 28, 2018

13.6K
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

903

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
172
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K